VYSIS SHIPS GENOSENSOR MICROARRAY SYSTEM FOR GENOMIC RESEARCH.
Vysis, Inc. (Nasdaq: VYSI), Downers Grove Downers Grove, village (1990 pop. 46,858), Du Page co., NE Ill.; settled 1832, inc. 1873. Downers Grove has undergone population growth and commercial development that include the construction of new office complexes. , Ill., has initiated customer shipments of its GenoSensor Microarray System. Initial placements have been made at customer sites in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. , Europe and Asia through Vysis' direct sales efforts and an extensive distribution network in 59 countries. Designed to simultaneously detect chromosomal amplifications or deletions of multiple genes in various human cancers, the Vysis GenoSensor Microarray System is the industry's first commercially available system that will enable researchers to rapidly identify and discover key genomic correlations in disease occurrence and outcome.
"The Vysis GenoSensor System has the potential to provide major breakthroughs in the understanding of cancer genetics," said Dr. Jerzy Lasota, M.D., Ph.D., molecular pathologist at the Department of Soft Tissue Pathology Soft tissue pathology is the subspecialty of surgical pathology which deals with the diagnosis and characterization of neoplastic and non-neoplastic diseases of the soft tissues, such as muscle, adipose tissue, tendons, fascia, and connective tissues. , Armed Forces Institute of Pathology Armed Forces Institute of Pathology A section of the US military which provides consultations, reference atlases and educational programs for pathologists , Washington, DC and one of Vysis' first GenoSensor customers. "A key advantage of this technology is that it enables one to look at a segment of the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. to see whether or not there have been key primary events such as a gene amplification Gene amplification
The process by which a cell specifically increases the copy number of a particular gene to a greater extent than it increases the copy number of genes composing the remainder of the genome (all the genes which make up the genetic machinery or deletion that are now known to be directly associated with the development and progression of cancer."
Utilizing Vysis' patented technology, the GenoSensor Microarray System includes genomic microarrays, reagents, instrumentation and analysis software. The system allows Vysis to compete in the rapidly expanding market for microarray products. Used in conjunction with expression microarrays, GenoSensor genomic microarrays can help researchers determine not only if a gene is present, but also whether the gene is found in abnormally high numbers, and if abnormal gene amplification is correlated with overexpression of an important protein.
"The GenoSensor Microarray System represents the second major technology platform that we have delivered to the marketplace." said John L. Bishop, president and chief executive officer of Vysis, Inc. "As the field of genomic research identifies new genes, correlations of these newly discovered genes to disease occurrence and outcomes will need to occur before clinical utility can be developed. We expect the GenoSensor Microarray System to allow Vysis to participate in this process thereby giving us a competitive advantage in the development of new clinical tests for genomic disease management," added Bishop.
The first commercially available microarray for the GenoSensor System, called the AmpliOnc(trademark) I, simultaneously detects abnormal increases in gene copy number from 58 different genes. Future GenoSensor Microarrays will add the ability to detect deletions of genes in addition to abnormal increases. Other microarrays will be developed that detect chromosomal aberrations Noun 1. chromosomal aberration - any change in the normal structure or number of chromosomes; often results in physical or mental abnormalities
chromosomal anomaly, chromosonal disorder, chrosomal abnormality in pre and post-natal applications.
More information about the GenoSensor System along with a complete listing of the genes present on AmpliOnc I can be found on the Vysis web site at www.vysis.com
Vysis, Inc. of Downers Grove, Ill., is a genomic disease management company that develops, commercializes and markets clinical products providing information critical to the evaluation and management of cancer, prenatal prenatal /pre·na·tal/ (-na´tal) preceding birth.
Preceding birth. Also called antenatal.
preceding birth. disorders and other genetic diseases. The company has direct sales operations in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. and Europe, a marketing partnership in Japan with Fujisawa Pharmaceutical Co., and a worldwide distribution network.